[go: up one dir, main page]

CA3015557A1 - L'utilisation de formules de burpenorphine a liberation constante pour le traitement de la douleur ou des troubles de consommation d'opioide - Google Patents

L'utilisation de formules de burpenorphine a liberation constante pour le traitement de la douleur ou des troubles de consommation d'opioide

Info

Publication number
CA3015557A1
CA3015557A1 CA3015557A CA3015557A CA3015557A1 CA 3015557 A1 CA3015557 A1 CA 3015557A1 CA 3015557 A CA3015557 A CA 3015557A CA 3015557 A CA3015557 A CA 3015557A CA 3015557 A1 CA3015557 A1 CA 3015557A1
Authority
CA
Canada
Prior art keywords
buprenorphine
opioid
composition
month
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA3015557A
Other languages
English (en)
Other versions
CA3015557C (fr
Inventor
Azmi NASSER
Christian Heidbreder
Celine M. Laffont
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indivior UK Ltd
Original Assignee
Indivior UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55221448&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3015557(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Indivior UK Ltd filed Critical Indivior UK Ltd
Publication of CA3015557A1 publication Critical patent/CA3015557A1/fr
Application granted granted Critical
Publication of CA3015557C publication Critical patent/CA3015557C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Addiction (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une utilisation de la buprénorphine pour le traitement dun trouble de consommation dopioïdes chez un humain en besoin de celui-ci comprenant une utilisation sous-cutanée dune composition pharmaceutique une fois par mois pendant au moins deux mois, dans laquelle la composition pharmaceutique comprend : (i) environ 300 mg dune base libre de buprénorphine; (ii) environ 32 % en poids dun copolymère de poly(DL-lactide-co-glycolide); et (iii) environ 50 % en poids de N-méthyl-2-pyrrolidone. Linvention concerne également des utilisations de la buprénorphine pour le traitement de troubles de consommation dopioïdes ou la réduction de manques dopioïdes chez un humain en besoin de celui-ci, comprenant une utilisation sous-cutanée dune composition pharmaceutique une fois par mois pendant au moins deux mois, dans laquelle la composition pharmaceutique comprend : (i) environ 300 mg dune base libre de buprénorphine; (ii) un copolymère de poly(DL-lactide-co-glycolide); et (iii) une N-méthyl-2-pyrrolidone.
CA3015557A 2014-11-07 2015-11-06 L'utilisation de formules de burpenorphine a liberation constante pour le traitement de la douleur ou des troubles de consommation d'opioide Active CA3015557C (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201462076854P 2014-11-07 2014-11-07
US62/076854 2014-11-07
US201562100391P 2015-01-06 2015-01-06
US62/100391 2015-01-06
US201562112546P 2015-02-05 2015-02-05
US62/112546 2015-02-05
US201562199778P 2015-07-31 2015-07-31
US62/199778 2015-07-31
CA2965895A CA2965895C (fr) 2014-11-07 2015-11-06 L'utilisation de formules de buprenorphine a liberation continue destinees au traitement de douleur ou de troubles lies a la consommationd'opioide

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2965895A Division CA2965895C (fr) 2014-11-07 2015-11-06 L'utilisation de formules de buprenorphine a liberation continue destinees au traitement de douleur ou de troubles lies a la consommationd'opioide

Publications (2)

Publication Number Publication Date
CA3015557A1 true CA3015557A1 (fr) 2016-05-12
CA3015557C CA3015557C (fr) 2019-07-16

Family

ID=55221448

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3015557A Active CA3015557C (fr) 2014-11-07 2015-11-06 L'utilisation de formules de burpenorphine a liberation constante pour le traitement de la douleur ou des troubles de consommation d'opioide
CA2965895A Active CA2965895C (fr) 2014-11-07 2015-11-06 L'utilisation de formules de buprenorphine a liberation continue destinees au traitement de douleur ou de troubles lies a la consommationd'opioide

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2965895A Active CA2965895C (fr) 2014-11-07 2015-11-06 L'utilisation de formules de buprenorphine a liberation continue destinees au traitement de douleur ou de troubles lies a la consommationd'opioide

Country Status (11)

Country Link
US (5) US20160128997A1 (fr)
EP (1) EP3215223B1 (fr)
AU (1) AU2015341490C1 (fr)
CA (2) CA3015557C (fr)
DK (1) DK3215223T3 (fr)
ES (1) ES2808150T3 (fr)
HK (1) HK1243368A1 (fr)
IL (1) IL251870A0 (fr)
NZ (1) NZ731309A (fr)
SG (1) SG11201703632WA (fr)
WO (1) WO2016071767A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3215223B1 (fr) 2014-11-07 2020-07-01 Indivior UK Limited Buprenorphine régime dosage
US10646484B2 (en) * 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
AU2018283724B2 (en) * 2017-06-16 2021-08-19 Indivior Uk Limited Methods to treat opioid use disorder
ES2965836T3 (es) 2018-01-22 2024-04-17 Foresee Pharmaceuticals Co Ltd Composición farmacéutica para administración de liberación mantenida de buprenorfina
WO2020077235A1 (fr) * 2018-10-11 2020-04-16 Indivior Uk Limited Buprénorphine pour traiter une dépression respiratoire
KR20210114940A (ko) * 2018-12-14 2021-09-24 페어 테라퓨틱스, 인코포레이티드 부프레노르핀-함유 제품들의 유도를 최적화하기 위한 디지털 치료 컴포넌트
US20220138539A1 (en) * 2020-10-30 2022-05-05 Element Ai Inc. Covariate processing with neural network execution blocks

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB784659A (en) 1954-11-26 1957-10-16 Upjohn Co Therapeutic compositions and aqueous suspensions thereof
US4599354A (en) 1985-03-11 1986-07-08 Morton Shulman Composition and method for producing prolonged pain relief
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5558880A (en) 1989-12-22 1996-09-24 Janssen Pharmaceutica Inc. Pharmaceutical and other dosage forms
NL9000634A (nl) 1990-03-20 1991-10-16 Catharina Ziekenhuis Stichting Suspensie-injectiepreparaat op waterbasis, werkwijze voor de bereiding daarvan en toepassing van dit preparaat voor pijnbestrijding.
US5069909A (en) 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US5486362A (en) 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
HU219487B (hu) 1993-11-19 2001-04-28 Janssen Pharmaceutica Nv. Riszperidont tartalmazó mikrorészecskék, eljárás előállításukra, alkalmazásuk és ezeket tartalmazó gyógyászati készítmények és előállításuk
BR9507313A (pt) 1994-04-08 1997-10-07 Atrix Lab Inc Composição liquida de liberação adequada para a formação de um implante de liberação controlada sistema polimérico curativo filmico microporoso biodegradável precursor de implante de liberação controlada para a implantação em um indivíduo polímero termoplástico solvente orgánico composicão de pré-polimero liquido componente de liberação controlada agente ativo uso da composição liquida de liberação e processos para forma um implante microporoso de liberação prolongada e para liberar um agente ativo em um individuo
US5453425A (en) 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation
US7833543B2 (en) 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US20030211157A1 (en) 1996-05-06 2003-11-13 Simon David Lew Semi-sol delivery blend for water soluble molecules
US5792477A (en) 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
CA2257303C (fr) 1996-06-17 2006-04-04 Janssen Pharmaceutica N.V. Formes posologiques biconvexes a desintegration rapide
US6261583B1 (en) 1998-07-28 2001-07-17 Atrix Laboratories, Inc. Moldable solid delivery system
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
JP4913298B2 (ja) 1999-08-27 2012-04-11 ブルックウッド ファーマシューティカルズ，インコーポレイティド 注射可能なブプレノルフィン微粒子組成物及びその使用
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
US6264987B1 (en) 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
WO2002067991A1 (fr) 2001-02-23 2002-09-06 Genentech, Inc. Polymeres erodables a injecter
US20040018238A1 (en) 2001-02-26 2004-01-29 Shukla Atul J Biodegradable vehicles and delivery systems of biolgically active substances
US6558702B2 (en) 2001-04-13 2003-05-06 Alkermes Controlled Therapeutics, Inc. Method of modifying the release profile of sustained release compositions
US20140271788A1 (en) 2013-03-15 2014-09-18 Monosol Rx, Llc Sublingual and buccal film compositions
JP5078217B2 (ja) 2001-11-14 2012-11-21 デュレクト コーポレーション 注入可能なデポー組成物およびそれらの使用
US7041320B1 (en) 2002-05-31 2006-05-09 Biotek, Inc. High drug loaded injectable microparticle compositions and methods of treating opioid drug dependence
AU2003240493B2 (en) 2002-05-31 2008-06-12 L. Molteni & C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. Implantable polymeric device for sustained release of buprenorphine
EP1581181B1 (fr) 2002-11-06 2008-12-24 ALZA Corporation Preparation de depot a liberation controlee
JP2006516963A (ja) 2003-02-04 2006-07-13 クリサリス テクノロジーズ インコーポレイテッド エアロゾル製剤及びブスピロン、ブプレノルフィン、トリアゾラム、シクロベンザプリン及びゾルピデムのエアロゾル送出
EP1622540A4 (fr) 2003-03-11 2009-12-30 Qlt Usa Inc Preparations d'agents anti-cancereux dependant du programme cellulaire
AU2004245022A1 (en) 2003-05-30 2004-12-16 Alza Corporation Implantable elastomeric depot compositions, uses thereof and method of manufacturing
CN101862455A (zh) 2003-06-26 2010-10-20 普西维达公司 原位胶凝的药物递送系统
FI20045223L (fi) 2004-06-15 2005-12-16 Bioretec Oy Monitoiminen biohajoava komposiitti ja kirurginen implantti, joka käsittää mainitun komposiitin
US20050032781A1 (en) 2003-08-06 2005-02-10 Elliot Ehrich Methods for administering active agents to CYP 2D6 sensitive patients
US20050048115A1 (en) 2003-08-27 2005-03-03 Murty Mangena Buprenorphine microspheres
US20050281879A1 (en) 2003-11-14 2005-12-22 Guohua Chen Excipients in drug delivery vehicles
US20050106214A1 (en) 2003-11-14 2005-05-19 Guohua Chen Excipients in drug delivery vehicles
US8329203B2 (en) 2004-01-12 2012-12-11 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
BRPI0511807C8 (pt) 2004-06-04 2021-05-25 Camurus Ab pré-formulação, processo de formação de uma pré-formulação e uso da mesma
US8313763B2 (en) 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
BRPI0516308A2 (pt) 2004-10-04 2010-06-15 Qlt Usa Inc composição fluida, métodos de tratamento de uma doença ou disfunção, métodos de liberação local ou sistêmica de um agente biológico, implantes, método de formação de um implante, kit de agente biológico e usos de uma composição fluida
AU2005304435B8 (en) 2004-11-10 2011-06-23 Tolmar Therapeutics, Inc. A stabilized polymeric delivery system
WO2006065951A2 (fr) 2004-12-15 2006-06-22 Qlt Usa, Inc. Preparation a liberation continue de composes d'octreotide
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
AU2006316607A1 (en) 2005-11-21 2007-05-31 Schering-Plough Pty. Limited Pharmaceutical compositions comprising buprenorphine
US20090239891A1 (en) 2006-03-01 2009-09-24 Shukla Atul J Sustained Release Dosage Forms of Analgesic Medications
US8076448B2 (en) 2006-10-11 2011-12-13 Tolmar Therapeutics, Inc. Preparation of biodegradable polyesters with low-burst properties by supercritical fluid extraction
DK2079767T3 (da) 2006-10-11 2014-10-27 Tolmar Therapeutics Inc Fremstilling af bionedbrydelige polyestere med lave burst-egenskaber ved ekstraktion med et superkritisk fluid
HRP20231117T3 (hr) 2007-02-15 2023-12-22 Tolmar International Limited Poli-(laktid-ko-glikolid) sa smanjenim efektom naglog oslobađanja
MX337286B (es) 2007-05-25 2016-02-22 Indivior Uk Ltd Formulaciones de transferencia sostenida de compuestos de risperidona.
MX2010002409A (es) 2007-09-03 2010-05-19 Nanotherapeutics Inc Composiciones y metodos para la distribucion de farmacos escasamente solubles.
US20090181068A1 (en) 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
KR101079513B1 (ko) * 2009-05-13 2011-11-03 삼성전기주식회사 범프 인쇄장치 및 그 제어방법
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2481018B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
US8975270B2 (en) * 2010-06-08 2015-03-10 Rb Pharmaceuticals Limited Injectable flowable composition comprising buprenorphine
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
DK2706986T3 (en) * 2011-09-19 2015-06-01 Orexo Ab NEW ADDICTION PREVENTING PHARMACEUTICAL COMPOSITION FOR TREATMENT OF OPIOID ADDICTION
SI2877155T1 (sl) 2012-07-26 2021-04-30 Camurus Ab Opioidne formulacije
TWI473863B (zh) 2012-12-19 2015-02-21 Nanya Plastics Corp 一種可剝離保護膜及其組成物配方
GB201404139D0 (en) * 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
GB201419091D0 (en) 2014-10-27 2014-12-10 Camurus Ab Formulations
EP3215223B1 (fr) 2014-11-07 2020-07-01 Indivior UK Limited Buprenorphine régime dosage
CN107257681A (zh) 2014-12-23 2017-10-17 卡姆拉斯公司 控释配制品
GB201516554D0 (en) 2015-09-18 2015-11-04 Camurus Ab Controlled-release formulations
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
AU2018283724B2 (en) 2017-06-16 2021-08-19 Indivior Uk Limited Methods to treat opioid use disorder

Also Published As

Publication number Publication date
AU2015341490B2 (en) 2020-08-13
NZ731309A (en) 2022-02-25
IL251870A0 (en) 2017-06-29
CA2965895A1 (fr) 2016-05-12
US11839611B2 (en) 2023-12-12
AU2015341490C1 (en) 2021-03-11
US20170354653A1 (en) 2017-12-14
US11000520B2 (en) 2021-05-11
US20220031692A1 (en) 2022-02-03
WO2016071767A1 (fr) 2016-05-12
US20180243292A1 (en) 2018-08-30
ES2808150T3 (es) 2021-02-25
HK1243368A1 (zh) 2018-07-13
CA3015557C (fr) 2019-07-16
AU2015341490A1 (en) 2017-05-18
EP3215223B1 (fr) 2020-07-01
EP3215223A1 (fr) 2017-09-13
US20160128997A1 (en) 2016-05-12
DK3215223T3 (da) 2020-08-03
SG11201703632WA (en) 2017-06-29
CA2965895C (fr) 2019-08-06
US20230077787A1 (en) 2023-03-16

Similar Documents

Publication Publication Date Title
US11839611B2 (en) Buprenorphine dosing regimens
Brown et al. Pharmacokinetics of escalating doses of oral psilocybin in healthy adults
Bisaga et al. The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone
Muehlan et al. Accelerated development of the dual orexin receptor antagonist ACT‐541468: integration of a microtracer in a first‐in‐human study
Laffont et al. Population pharmacokinetic modeling after repeated administrations of RBP‐6000, a new, subcutaneously injectable, long‐acting, sustained‐release formulation of buprenorphine, for the treatment of opioid use disorder
Fudala et al. Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts
Roux et al. Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone
Webster et al. Impact of intravenous naltrexone on intravenous morphine-induced high, drug liking, and euphoric effects in experienced, nondependent male opioid users
Jones et al. Population pharmacokinetics of a monthly buprenorphine depot injection for the treatment of opioid use disorder: a combined analysis of phase II and phase III trials
Gomeni et al. A model‐based approach to characterize the population pharmacokinetics and the relationship between the pharmacokinetic and safety profiles of RBP‐7000, a new, long‐acting, sustained‐released formulation of risperidone
JPH09508967A (ja) 患者が薬剤処方に従っているかどうかをモニターする方法
Nasser et al. A population pharmacokinetic and pharmacodynamic modelling approach to support the clinical development of RBP-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid dependence
Olofsen et al. Modeling buprenorphine reduction of fentanyl-induced respiratory depression
Ivaturi et al. Exposure‐response analysis after subcutaneous administration of RBP‐7000, a once‐a‐month long‐acting Atrigel formulation of risperidone
Saari et al. Clinical pharmacokinetics and pharmacodynamics of naloxone
US10646484B2 (en) Methods to treat opioid use disorder
US20190015415A1 (en) Methods for treating schizophrenia
Babalonis et al. Relative potency of intravenous oxymorphone compared to other µ opioid agonists in humans—pilot study outcomes
Lachi-Silva et al. Population pharmacokinetics of orally administrated bromopride: Focus on the absorption process
Webster et al. Intranasal pharmacokinetics of morphine ARER, a novel abuse‐deterrent formulation: results from a randomized, double‐blind, four‐way crossover study in nondependent, opioid‐experienced subjects
Malinky et al. DARK classics in chemical neuroscience: Loperamide
AU2018283724B2 (en) Methods to treat opioid use disorder
WO2017059106A1 (fr) Traitement psychiatrique pour des patients à polymorphismes génétiques
CA2995923C (fr) Methodes de traitement de troubles lies a l'utilisation d'opioide
Lu et al. Factors influencing blood prolactin levels in patients with Schizophrenia under Risperidone treatment

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180828